Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.
Verici Dx plc
Developer of personalised patient tests for organ transplants
Company information
Company:
Public
Fund:
AIM EIS Fund, EIS Portfolio Service, Growth Capital VCT
Sector:
Medical
Status:
Current
Investment Date:
03/2022
You might also be interested in...
Developer and manufacturer of advanced Surface Acoustic Wave sensors